WARSAW STOCK EXCHANGE/ PLGPW0000017 /
| 8/22/2024 6:42:33 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 11.0000USD | - | 1,000 Turnover: 1,900 |
-Bid Size: - | -Ask Size: - | 434.49 mill.USD | - | - |
GlobeNewswire
7/9
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsych...
GlobeNewswire
6/24
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for u...
GlobeNewswire
6/17
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in...
GlobeNewswire
5/28
Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumou...
GlobeNewswire
5/21
Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatmen...
GlobeNewswire
4/4
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Tre...
GlobeNewswire
4/3
Molecure has published its financial report for 2023 - the company has significantly accelerated the...
GlobeNewswire
3/22
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
GlobeNewswire
3/11
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing ...
GlobeNewswire
1/30
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoim...
GlobeNewswire
1/16
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
GlobeNewswire
12/11/2023
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Me...
GlobeNewswire
12/7/2023
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
GlobeNewswire
11/29/2023
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
10/31/2023
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
GlobeNewswire
10/23/2023
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Soli...
GlobeNewswire
10/4/2023
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2...
GlobeNewswire
9/29/2023
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
GlobeNewswire
9/13/2023
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
Newsfile Corp
8/8/2022
Monaco Foundry Partners with Carlson Investments SE (Carlson VC), a Publicly Listed Venture Capital ...
GlobeNewswire
9/24/2021
Getka and Unimot to Power Projects in Poland with American-Made Solar Panels from First Solar
GlobeNewswire
6/22/2021
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in ...
